A report from Persistence Market Research has revealed that increasing uptake for indigestible medical devices will drive global demand for smart pills during 2017 to 2026.
Novacap has agreed to acquire Boston-based PCI Synthesis, a pharmaceutical contract development and manufacturing organization (CDMO), for an undisclosed price.
A new £56m medicines manufacturing innovation center (MMIC) is to be established in Renfrewshire, Scotland, to offer businesses support to transform processes and technologies.
NeuroVive Pharmaceutical has granted exclusive license of a subset of succinate prodrug chemistry under its NVP015 program to BridgeBio Pharma.
Sage Therapeutics and Shionogi & Co. have agreed to collaborate for the clinical development and commercialization of the former’s SAGE-217 for the treatment of major depressive disorder (MDD) and other indications in Japan, Taiwan and South Korea.
BridgeBio Pharma has entered into an agreement with Alexion Pharmaceuticals to acquire cyclic pyranopterin monophosphate (cPMP; ALXN1101), a synthetic enzyme co-factor therapy for patients with the ultra-rare disease caused by molybdenum cofactor deficiency (MoCD) Type A.
Sanofi Pasteur, the vaccines business of French pharma firm Sanofi, has agreed to acquire exclusive license of Translate Bio’s mRNA technology to develop messenger RNA (mRNA) vaccines in a deal that could be worth up to $805m.
Oncologie is launching operations in both Boston and Shanghai with $16.5m seed financing led by Pivotal bioVenture Partners China.
Sirnaomics, a biopharmaceutical company in development of RNAi therapeutics, has closed Series C1 financing of $25m.
Pfizer said that it will invest $600m in biotechnology and other emerging growth firms through its venture capital arm Pfizer Ventures for the development of life-changing therapies to patients in need.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.